Antigen News and Research RSS Feed - Antigen News and Research

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies. [More]
Creating more effective vaccines against flu virus

Creating more effective vaccines against flu virus

Flu vaccines can be something of a shot in the dark. Not only must they be given yearly, there's no guarantee the strains against which they protect will be the ones circulating once the season arrives. New research by Rockefeller University scientists and their colleagues suggests it may be possible to harness a previously unknown mechanism within the immune system to create more effective and efficient vaccines against this ever-mutating virus. [More]
Research finding could lead to first effective therapies, vaccines against dengue virus

Research finding could lead to first effective therapies, vaccines against dengue virus

Researchers at Vanderbilt University and the National University of Singapore have determined the structure of a human monoclonal antibody which, in an animal model, strongly neutralizes a type of the potentially lethal dengue virus. [More]
FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

FDA accepts Adaptimmune’s IND application for MAGE-A10 T therapeutic candidate to combat NSCLC

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration has accepted the Company's investigational new drug (IND) application for autologous genetically modified T-cells expressing enhanced T cell receptors specific for MAGE A10 (MAGE-A10 T) in patients with locally advanced or metastatic non-small cell lung cancer, and that the IND is now active. [More]
NDSU researcher awarded $1.35 million research grant to develop targeted treatment for colorectal cancer

NDSU researcher awarded $1.35 million research grant to develop targeted treatment for colorectal cancer

A researcher at North Dakota State University, Fargo, is receiving a four-year $1.35 million research project grant from the National Cancer Institute of the National Institutes of Health to develop a targeted treatment for colorectal cancer. [More]
Scientists develop olfactory fingerprint test to identify individuals from sense of smell

Scientists develop olfactory fingerprint test to identify individuals from sense of smell

Each of us has, in our nose, about six million smell receptors of around four hundred different types. The distribution of these receptors varies from person to person - so much so that each person's sense of smell may be unique. [More]
Hepatic ALT flares linked to HBsAg clearance

Hepatic ALT flares linked to HBsAg clearance

Hepatic alanine aminotransferase flares are associated with rapid decline and greater annual reductions of hepatitis B surface antigen in patients with chronic hepatitis B virus infection who achieve HBsAg seroclearance, say Japanese researchers. [More]
Asterias Biotherapeutics added to Russell indexes

Asterias Biotherapeutics added to Russell indexes

Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced that it has been added to the Russell 2000, Russell 3000, Russell Global and Russell Microcap indexes following Russell Investments' ("Russell") reconstitution of its comprehensive set of U.S. and global equity indexes after the close of the U.S. markets on June 26, 2015. [More]
SLU's Center for Vaccine Development receives $2.9 million to study new vaccine to combat TB

SLU's Center for Vaccine Development receives $2.9 million to study new vaccine to combat TB

Saint Louis University's Center for Vaccine Development has received a $2.9 million award from the Bill & Melinda Gates Foundation to study a new tuberculosis vaccine. [More]
Exhausted army of immune cells may damage the very body they are supposed to protect

Exhausted army of immune cells may damage the very body they are supposed to protect

An 'exhausted' army of immune cells may not be able to fight off infection, but if its soldiers fight too hard they risk damaging the very body they are meant to be protecting, suggests new research from the University of Cambridge. [More]

FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell’s Investigational New Drug application for the company’s lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease. [More]
Study opens up new line of research into origin of digestive diseases

Study opens up new line of research into origin of digestive diseases

There are numerous studies related to the absorption of nutrients from the stomach since understanding what happens in our digestive system is crucial, for example, in order to be able to avoid in the future some of the diseases that affect part of the population to a lesser or greater extent. [More]
Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline. [More]
Ebola diagnosis now possible within minutes

Ebola diagnosis now possible within minutes

The Lancet has published details of a new point-of-care test for Ebola virus that is as sensitive as the conventional laboratory test, but provides results within minutes. [More]
Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Biontech, Siemens enter into strategic collaboration on manufacture of personalized cancer vaccines

Siemens and BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, have entered into a strategic collaboration. [More]
Researchers develop protective vaccine against chlamydia infections

Researchers develop protective vaccine against chlamydia infections

Chlamydiae are the most common, sexually transmitted, bacterial pathogens in the world. Every year around 100 million people contract Chlamydia infections, which are one of the main causes of female infertility and ectopic pregnancies and can also lead to blindness - especially in developing countries. [More]
Investments in cloud-based laboratory information management systems are part of Europe’s eHealth strategy

Investments in cloud-based laboratory information management systems are part of Europe’s eHealth strategy

Investments in cloud-based laboratory information management systems are part of Europe’s eHealth strategy. [More]

TxCell’s pilot manufacturing facility activities put on temporary partial hold

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that it has temporarily put its pilot manufacturing facility activities at Besançon, France on partial hold. [More]
Northeastern professor receives $1.4 million NIH grant to design microfluidic devices for vaccine development

Northeastern professor receives $1.4 million NIH grant to design microfluidic devices for vaccine development

North­eastern pro­fessor of chem­ical engi­neering Shashi Murthy has received a four-year, $1.4 mil­lion award from the National Insti­tutes of Health to develop a novel instru­ment that would auto­mate an impor­tant process used in cre­ating effec­tive vaccines. [More]
Targeted molecular-imaging method could help identify early stages of prostate cancer

Targeted molecular-imaging method could help identify early stages of prostate cancer

A targeted molecular-imaging method under development at Rochester Institute of Technology could help detect early stages of prostate cancer and improve image-directed biopsies. [More]
Advertisement
Advertisement